SCHEMBL3650683

SCHEMBL3650683

CC(C)(C(=O)O)C(O)CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PGD P52209 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.40
HMGCR P04035 1/20 0.40
CHRM1 P11229 1/20 0.40
TBXA2R P21731 1/20 0.40
ADRA1A P35348 1/20 0.40
TSHR P16473 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
HIF1A Q16665 1/20 0.39
MAPT P10636 2/20 0.38
GABRR1 P24046 2/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GPR84 Q9NQS5 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4807998 0.79 PGD (0.43) PGDSLC22A6SMN1; SMN2TSHRMAPT
SCHEMBL4806982 0.79 PGD (0.43) PGDSLC22A6SMN1; SMN2TSHRMAPT
SCHEMBL667280 0.79 PGD (0.50) PGDSLC22A6SMN1; SMN2HMGCRCHRM1
SCHEMBL6803525 0.79 PGD (0.50) PGDSLC22A6SMN1; SMN2HMGCRCHRM1
SCHEMBL6805671 0.79 PGD (0.50) PGDSLC22A6SMN1; SMN2HMGCRCHRM1
SCHEMBL5464437 0.77 OR51E2 (0.38) PGDHMGCRCHRM1TBXA2RADRA1A
SCHEMBL29875674 0.77 TSHR (0.40) PGDSLC22A6SMN1; SMN2HMGCRCHRM1
Ammonia Solution, Strong SCHEMBL27881579 0.77 PGD (0.48) PGDSLC22A6SMN1; SMN2HMGCRCHRM1
SCHEMBL3646440 0.77 TSHR (0.50) PGDHMGCRCHRM1TBXA2RADRA1A
SCHEMBL249850 0.75 TSHR (0.39) PGDSLC22A6SMN1; SMN2HMGCRCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0961795-A1 ACID FUNCTIONALIZED POLYURETHANE ADDUCTS THE DOW CHEMICAL COMPANY (US) 1999-12-08 EP claimed
WO-1998037113-A1 ACID FUNCTIONALIZED POLYURETHANE ADDUCTS THE DOW CHEMICAL COMPANY (US) 1998-08-27 WO claimed
US-20210139390-A1 PRODUCTION METHOD OF ORGANIC COMPOUND UNITIKA LTD. (JP) 2021-05-13 US disclosed
EP-3819283-A1 METHOD FOR PRODUCING ORGANIC COMPOUND Unitika Ltd. (JP) 2021-05-12 EP disclosed
EP-2178846-A1 ROSUVASTATIN INTERMEDIATES AND THEIR PREPARATION Teva Pharmaceutical Industries Ltd. (IL) 2010-04-28 EP disclosed
US-20090069563-A1 Rosuvastatin intermediates and their preparation TEVA PHARMACEUTICALS USA, INC. 2009-03-12 US disclosed
WO-2009009152-A1 ROSUVASTATIN INTERMEDIATES AND THEIR PREPARATION TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-01-15 WO disclosed
US-6610629-B2 Process for producing an oxide catalyst for oxidation or ammoxidation ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-08-26 US disclosed
US-20030017944-A1 Process for producing an oxide catalyst for oxidation or ammoxidation ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-01-23 US disclosed
EP-0961795-A1 ACID FUNCTIONALIZED POLYURETHANE ADDUCTS THE DOW CHEMICAL COMPANY (US) 1999-12-08 EP disclosed
US-5936055-A Acid functionalized polyurethane adducts THE DOW CHEMICAL COMPANY (US) 1999-08-10 US disclosed
WO-1998037113-A1 ACID FUNCTIONALIZED POLYURETHANE ADDUCTS THE DOW CHEMICAL COMPANY (US) 1998-08-27 WO disclosed
EP-0168480-A4 PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID. WISCONSIN ALUMNI RES FOUND (US) 1987-10-08 EP disclosed
US-4584270-A ENZYME CLEAVAGE OF ESTER GROUPING OF 3-HYDROXYGLUTARIC ACID DIESTER, FOLLOWED BY CHEMICAL CONVERSION WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1986-04-22 US disclosed
EP-0168480-A1 PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1986-01-22 EP disclosed
WO-1985003307-A1 PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1985-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069563-A1 Rosuvastatin intermediates and their preparation HMGCR, PCSK9, PCSK7 PGD 965/4885SLC22A6 2065/4885SMN1; SMN2 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.